The Rising Prevalence Of Hodgkin Lymphoma And Increasing Awareness Regarding Hodgkin Lymphoma To Boost The Hodgkin Lymphoma Treatment Market Growth
The Hodgkin Lymphoma Treatment Market is Segmented by Treatment Type (Chemotherapy, Radiotherapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). Size, Share, Outlook, and Opportunity Analysis, 2023-2030
The global Hodgkin Lymphoma Treatment Market is estimated to be valued at reach US$ 15.8 Billion by 2030 and is expected to exhibit a CAGR of 8.4 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The major treatment for Hodgkin lymphoma is chemotherapy, or chemotherapy and the radiotherapy. Rarely, chemotherapy may be coupled with steroid drugs. Some patients also have biological drugs. Operation isn't usually utilized to cure the problem, excluding the biopsy utilized to analyze it.
Competitive Landscape:
Key players involved in the growth of the global Hodgkin Lymphoma Treatment Market are Biogen Inc., Incyte Corp, Alkem Laboratories, F Hoffmann-La Roche Ltd, Amneal Pharmaceuticals, Inc., Merck & Co. Inc., Seagen Inc., Baxter International Inc., Bristol-Myers Squibb Company, and Teva Pharmaceutical Industries Ltd.
Market Key Drivers:
The rising prevalence of Hodgkin lymphoma and increasing awareness regarding Hodgkin Lymphoma is expected to augment the growth of the global Hodgkin lymphoma treatment for market. For instance, as per the ACS around 8,540 people suffer from Hodgkin Lymphoma in U.S.
Various research survey on the efficiency of better therapeutics have been performed and are enhancing the awareness associated to the disorders and their therapeutics is projected to propel the growth of global Hodgkin Lymphoma Treatment Market. For instance, in June 2022, a research survey was published named Brentuximab vedotin and linked with event-free survival in kids with recently analyzed high-threat Hodgkin lymphoma.
Competitive Landscape:
The COVID-19 outbreak was projected to have a significant effect on the growth of global Hodgkin lymphoma treatment for market due to the global spread of the COVID-19 pandemic, the market's growth reduced drastically. Along with the public health restrictions of the COVID-19, there was a delay and interruption of surgical services across the globe, which had severe effects for patients with medical problems and surgical facilities.
The rising regulatory body approval of pharmaceutical treatments for the Clostridioides Difficile Infection Treatment Market may be a major factor in the expansion of the market for treating this infection.
Key Takeaways:
The global Hodgkin Lymphoma Treatment Market is anticipated to exhibit a CAGR at higher rate during the forecast period due to rising use of radiotherapy technique for Hodgkin disease. For instance, In June 2020, as per a survey report published in Radiation therapeutics for Advanced-Stage Hodgkin Lymphoma declared that as per the ACS, Hodgkin lymphoma is a rare disorder, with around 8110 new incidences and 1000 deaths due to Hodgkin lymphoma in 2019.
Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the global Hodgkin lymphoma treatment for market due to rising cases of Hodgkin Lymphoma, increasing investments, rising developments. For instance, as per the Globocan 2020 report, around 9,077 new incidences of Hodgkin lymphoma tumor were analyzed in the North American region in 2020 and by 2040, this count is projected to cross 10,346 cases, around 14% rise from 2020.
Comments
Post a Comment